Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI takes on kidney disease: a new model to forecast Who's at risk

NCT ID NCT07751939

Knowledge-focused Sponsor: University Medical Center Ho Chi Minh City (UMC) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study aims to develop an artificial intelligence-based model to predict serious outcomes in people with chronic kidney disease (CKD), such as disease progression, kidney failure, or death. Researchers will follow over 1,100 adults with moderate CKD in Vietnam for two years, using routine blood and urine tests and health information to train and compare several machine learning algorithms. The goal is to create a tool that helps doctors identify high-risk patients earlier and tailor treatments to slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence-based prediction model using machine learning algorithms
What this could lead to
If successful, this could lead to a practical tool that helps doctors identify high-risk kidney disease patients earlier, enabling timely treatment and better outcomes.
What could go wrong
The model is being developed and tested in a specific population, so it may not work for everyone. Also, it's a prediction tool, not a treatment, and its accuracy needs validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,182 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with chronic kidney disease managed at the University Medical Center Ho Chi Minh City.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>= 18 years. * eGFR 20-60 mL/min/1.73 m2, stable for at least 3 months before enrolment. * Provides written informed consent to participate. Exclusion Criteria: * Currently receiving kidney replacement therapy (haemodialysis, peritoneal dialysis, or kidney transplant). * Acute illness at enrolment (acute infection, acute heart failure, or progressive liver disease). * Current malignancy. * Life expectancy \< 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease

Contacts and locations

Locations

  • University of Medicine and Pharmacy at HCMC

    Ho Chi Minh City, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.